Log in
The Cybernetics team at the University of Reading works at the frontier of human-machine interaction. The group carries out research on therapy and human enhancement in collaboration with medical professionals, to research new therapeutic treatments for patients with paralysis. Our work has led to the first human implantation of BrainGate, an intelligent deep brain stimulator, and the culturing of neurons within a robot body. Our work has been used by neurosurgeons in experimental human trials with the aim to enhance the standard of living of paralysed individuals. This ground breaking, and sometimes controversial work, has sparked widespread discussion and debate in the public sphere, within the media and at the government level, on the use of machines to enhance humans and vice versa.
Professor Malcolm Young and colleagues at Newcastle University developed new mathematical and computational tools with which they could analyse large amounts of data on connections in the brain and produce models of how the brain is organised. Young realised that those research tools could also be used to analyse networks of proteins involved in disease processes and predict their susceptibility to drugs and in 2003 he set up the medicines discovery company e-Therapeutics to exploit the technology. The company listed on the AIM of the London Stock Exchange in November 2007 and in May 2013 became the eighth largest company in the biotechnology/pharmaceutical sector listed on the index, with a market capitalisation of over £90 million.
Researchers at the Biomedical Research Network (BRN) at The Open University (OU) have developed two novel technologies:
These patented technologies have been adopted by industrial partners, who have either invested in their further development and the automation of the production process to generate neural tissue model kits or have adopted the technology for their own use following licence transfer and/or temporary industrial contracts.
3D polyHIPE scaffold materials and synthetic retinoids developed at Durham University for applications in cell biology have been commercialized by Reinnervate, a Durham spin-out company, using a patent/licensing strategy. Reinnervate has raised £8m venture capital investment and has employed an average of 12 FTE staff since 2008, peaking at 27 in 2012. Polystyrene-based highly porous polyHIPE materials which act as 3D in vitro cell culture scaffolds were launched under the Alvetex® brand in November 2010 and a retinoid derivative, designed to control cellular development including stem cell differentiation down neural pathways, was launched as ec23®. The products have won several awards and Alvetex® was voted one of "The Scientist" magazine's top 10 Life Science Innovations of 2010.
Neural stem cells offer enormous therapeutic potential for stroke but they require regulatory approval. Researchers at King's College London (KCL) devised a technology to immortalise stem cells, generated clinical-grade neural stem cell lines and demonstrated efficacy in an animal model of stroke. KCL research underpins the first approvals in the UK for a therapeutic stem cell product. This led to an industry-sponsored clinical trial of a stem cell therapeutic that has demonstrated vital improvement in all the first five stroke patients treated. KCL research has made a significant impact by considerably reducing the timetable for delivering potential therapies which will affect the life sciences industry and the process now in place acts as a model for other technology developments in this area.
Alzheimer's disease is the most common form of dementia, with a cost to society estimated at €177 billion per annum across Europe, according to the European Collaboration on Dementia (EuroCoDe) project funded by Alzheimer Europe. Data-based modelling of network structures is a modern approach to study and understand many diseases including dementia. Research carried out at the Institute of Pure and Applied Mathematics (IPAM) at the University of Aberdeen has led to the development, implementation, and testing of novel mathematical algorithms to infer network structures by means of observations of their dynamics. The results of our research have been implemented as part of a software package now offered by the Netherlands-based company BrainMarker to researchers and practitioners across Europe in an online `pay-per-click' platform (section 5.c1 and 5.c4). As such our research generated impact on clinical practitioners in addition to commercial impact.
New computational analysis methods have been developed to make drug discovery and toxicological analysis much more efficient. These methods have been patented (UK, EU, US) and are employed in e-Therapeutics Plc, a computational drug discovery spin-off company of the University. The company, introduced to the Alternative Investment Market of the London Stock Exchange in 2007, is now the eighth largest company (by market capitalisation - £92.7M (26/6/2013)) in the pharma/biotech sector. The underlying technologies derive from network analysis and workflow research at the University. The company has an anti-cancer drug (ETS2101) in phase I clinical trials in the UK and the US, and an anti-depression drug (ETS6103) planned to enter phase IIb clinical trial shortly. The beneficiaries of this research are e- Therapeutics directly, other drug companies, and ultimately patients.
Seven patients with avascular necrosis of the femoral head and bone cysts have been treated successfully with skeletal stem cell therapy, developed by Southampton researchers, resulting in an improved quality of life. This unique multi-disciplinary approach linking nano-bioengineering and stem cell research could revolutionise treatment for the 4,000 patients requiring surgery each year in the UK and reduce a huge financial burden on the NHS. The work has been granted three patents and the team are in discussions on development of the next generation of orthopaedic implants with industry.
In 2008, Professors Martin Birchall and Anthony Hollander (University of Bristol) and a team of scientists and surgeons led from Bristol successfully created and then transplanted the first tissue-engineered trachea (windpipe), using the seriously ill patient's own stem cells. The bioengineered trachea immediately provided the patient with a normally functioning airway, thereby avoiding higher risk surgery or life-long immunosuppression. This sequence of events, which raised public interest and understanding around the world as a result of huge media coverage, acted as proof of concept for this kind of medical intervention. A new clinical technology with far-reaching implications for patients had passed a major test. This development demonstrated the potential of stem cell biology and regenerative medicine to eradicate disease as well as treat symptoms and has already led to the implantation of bioengineered tracheas in at least 14 other patients.
We were the first to show that human stem cells could be used to create functional organ replacements in patients. These transplants, first performed to save the life of an adult in 2008, and then repeated to save a child in 2010, have changed the way the world views stem cell therapies. We have opened the door to a future where conventional transplantation, with all its technical, toxicity and ethical problems, can be replaced and increased in range by a family of customised organ replacements, populated by cells derived from autologous stem cells. This has altered worldview, changed clinical practice and had key influences on UK policy.